DK0540588T3 - Preparation providing improved clearance of bioactive substances from the blood stream - Google Patents

Preparation providing improved clearance of bioactive substances from the blood stream

Info

Publication number
DK0540588T3
DK0540588T3 DK91913278.7T DK91913278T DK0540588T3 DK 0540588 T3 DK0540588 T3 DK 0540588T3 DK 91913278 T DK91913278 T DK 91913278T DK 0540588 T3 DK0540588 T3 DK 0540588T3
Authority
DK
Denmark
Prior art keywords
bioactive substances
blood stream
providing improved
improved clearance
ligand
Prior art date
Application number
DK91913278.7T
Other languages
Danish (da)
Inventor
Johan Selmer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0540588T3 publication Critical patent/DK0540588T3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

A pharmaceutical or diagnostic composition comprises, in separate containers, (a) a capturing agent capable of binding to a bioactive substance as well as to a ligand or ligand analogue which is able to bind to a cellular receptor; and (b) a ligand or ligand analogue capable of binding to a cellular receptor as well as to said capturing agent. The composition may be used for providing the rapid clearance of bioactive substances from the circulation.
DK91913278.7T 1990-07-24 1991-07-24 Preparation providing improved clearance of bioactive substances from the blood stream DK0540588T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK176290A DK176290D0 (en) 1990-07-24 1990-07-24 THERAPEUTIC AND DIAGNOSTIC PREPARATION

Publications (1)

Publication Number Publication Date
DK0540588T3 true DK0540588T3 (en) 1995-11-06

Family

ID=8107861

Family Applications (2)

Application Number Title Priority Date Filing Date
DK176290A DK176290D0 (en) 1990-07-24 1990-07-24 THERAPEUTIC AND DIAGNOSTIC PREPARATION
DK91913278.7T DK0540588T3 (en) 1990-07-24 1991-07-24 Preparation providing improved clearance of bioactive substances from the blood stream

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK176290A DK176290D0 (en) 1990-07-24 1990-07-24 THERAPEUTIC AND DIAGNOSTIC PREPARATION

Country Status (11)

Country Link
EP (1) EP0540588B1 (en)
JP (1) JPH05509092A (en)
AT (1) ATE123951T1 (en)
AU (1) AU659092B2 (en)
CA (1) CA2087971A1 (en)
DE (1) DE69110679T2 (en)
DK (2) DK176290D0 (en)
FI (1) FI930269A (en)
GR (1) GR3017362T3 (en)
NO (1) NO930218L (en)
WO (1) WO1992001469A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
KR100452125B1 (en) * 2002-07-30 2004-10-12 주식회사 바이오알앤즈 Novel Bacillus subtilis BRD-007 strain having food waste decompositing capability and microbial agent for food waste treatment using it
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484198D1 (en) * 1983-07-29 1991-04-04 Milton David Goldenberg METHOD FOR INCREASING TARGET SPECIFICITY IN ANTIBODY DETERMINATIONS AND FOR CLEARING NON-TARGET SPECIFIC DIAGNOSTIC AND THERAPEUTIC FACTORS.
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) * 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
ATE123951T1 (en) 1995-07-15
NO930218L (en) 1993-03-24
GR3017362T3 (en) 1995-12-31
DE69110679D1 (en) 1995-07-27
FI930269A0 (en) 1993-01-22
EP0540588B1 (en) 1995-06-21
EP0540588A1 (en) 1993-05-12
AU659092B2 (en) 1995-05-11
DE69110679T2 (en) 1995-11-09
AU8282891A (en) 1992-02-18
WO1992001469A1 (en) 1992-02-06
NO930218D0 (en) 1993-01-22
CA2087971A1 (en) 1992-01-25
FI930269A (en) 1993-03-22
JPH05509092A (en) 1993-12-16
DK176290D0 (en) 1990-07-24

Similar Documents

Publication Publication Date Title
MX9203370A (en) DESULFATOHIRUDINA AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
DE69230670D1 (en) COMPOSITIONS CONTAINING A BLOOD CLOTH POLYMER MATRIX FOR THE ADMINISTRATION OF OSTEOGENIC PROTEINS
ATE2271T1 (en) 4-(SUBSTITUTED THIAZOLYL)-3-HYDROXY-3-PYRROLINE2,5-DIONE COMPOUNDS, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
ATE83374T1 (en) NEW GALENIC FORM OF FENOFIBRATE.
ATE7697T1 (en) SUBSTITUTED PYRAZINYL-1,2,4-OXADIAZOLE-5-ONE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DK0497240T3 (en) Composition for controlled release of active substances for ruminants
MX9102353A (en) N, O-SULPHATES OF HEPAROSANES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINED IN THEM.
BR9711098B1 (en) heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
ATE26705T1 (en) 1-CARBOXYALKANOYLINDOLINE-2-CARBONIC ACIDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS.
MX9305146A (en) CONJUGATE OF INTERFERON, PROCEDURE FOR ITS PRERATION AND PHARMACEUTICAL COMPOSITION THAT CONTAIN IT.
DK0399902T3 (en) Porous pharmaceutical formulation and preparation thereof
MX9102500A (en) BIPHENYLIUM COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE59813229D1 (en) STABLE EXTRACT OF HYPERICUM PERFORATUM L., PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL PREPARATIONS
BR9306345A (en) Methods to suppress the ability of a mammal's t-cells to proliferate and to suppress immune response compositions for use in suppressing the ability of t-cells to proliferate and in suppressing the immune response
ATE222897T1 (en) SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX24890A (en) SYNTHETIC POLYPEPTIDE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT.
DK0540588T3 (en) Preparation providing improved clearance of bioactive substances from the blood stream
DE3887068D1 (en) 2,2-Dimethylchromene derivatives, process for their preparation and pharmaceutical compositions containing them.
ATE8880T1 (en) NEW CARBAMATS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
ES488301A0 (en) PROCEDURE FOR OBTAINING DEHYDROPEPTIDES
DE3850044D1 (en) Azelastine embonate, process for its preparation and pharmaceutical preparations containing azelastine embonate as active ingredient.
DE3879837D1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CERBERAL PSYCHO-ORGANIC SYNDROME.
ATE111461T1 (en) N-((2-THENOYLMERKAPTO-3-METHYL)-BUTANOYL>- HOMOCYSTEIN THIOLACTONE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE49956T1 (en) N,N-BIS-(4FLUOROPHENYL)CARBAMOYLACETOHYDROXAMS|URE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE22288T1 (en) PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.